Viviana A Simon, MD, PhD
img_Viviana A Simon
PROFESSOR | Microbiology
PROFESSOR | Pathology, Molecular and Cell Based Medicine
PROFESSOR | Medicine, Infectious Diseases
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Microbiology [MIC]

Specific Clinical/Research Interest:
HIV pathogenesis and host-virus interactions
Current Students: Mawuena Binka, Susan Majdak
Postdoctoral Fellows: Marcel Ooms
Research Personnel: Ariana Harari

Summary of Research Studies:
My research focuses on HIV-1 pathogenesis and viral host interactions. Complex organisms evolved both innate and adaptive immune defenses to prevent viral infection and/or dissemination. Recently,it became apparent that a group of constitutively expressed genes can efficiently restrict replication of endogenous and exogenous viruses in a species specific manner. Host cells use DNA/RNA editing enzymes as ways to curb invasion from viruses. For example, human APOBEC3G (APOlipoprotein B Editing Complex 3G) has been shown to be active against exogenous retroviruses (HIV-1, HIV-2, Foamy), endogenous mobile genetic elements (e.g., LTR retrotransposons) and DNA viruses (e.g., Hepatitis B). One of the mode of action of cytidine deaminases is one of extensive mutagenesis. The HIV-1 gene Vif effectively counters the antiretroviral activity of APOBEC3G by inducing its degradation. The nucleotide composition of the HIV-1 genome suggests, however, that protection from host-mediated viral cDNA deamination may not be absolute. We have shown that Vif alleles that fail to degrade APOBEC3G, APOBEC3F or both can be detected in vivo. We speculate that intrinsic restriction mediated by cytidine deaminases contributes to HIV-1 sequence diversification.

Residency, Auguste Viktoria Hospital

The Rockefeller University

The Rockefeller University

MD, Humboldt University

PhD, University of Rostock


Sinsheimer Scholar (Alexandrine and Alexander L. Sinsheimer Fund)


Selected Publications

Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study. Al Ozonoff, Naresh Doni Jayavelu, Shanshan Liu, Esther Melamed, Carly E. Milliren, Jingjing Qi, Linda N. Geng, Grace A. McComsey, Charles B. Cairns, Lindsey R. Baden, Joanna Schaenman, Albert C. Shaw, Hady Samaha, Vicki Seyfert-Margolis, Florian Krammer, Lindsey B. Rosen, Hanno Steen, Caitlin Syphurs, Ravi Dandekar, Casey P. Shannon, Rafick P. Sekaly, Lauren I.R. Ehrlich, David B. Corry, Farrah Kheradmand, Mark A. Atkinson, Scott C. Brakenridge, Nelson I.Agudelo Higuita, Jordan P. Metcalf, Catherine L. Hough, William B. Messer, Bali Pulendran, Kari C. Nadeau, Mark M. Davis, Ana Fernandez Sesma, Viviana Simon, Harm van Bakel, Seunghee Kim-Schulze, David A. Hafler, Ofer Levy, Monica Kraft, Chris Bime, Elias K. Haddad, Carolyn S. Calfee, David J. Erle, Charles R. Langelier, Walter Eckalbar, Steven E. Bosinger, Bjoern Peters, Steven H. Kleinstein, Elaine F. Reed, Alison D. Augustine, Joann Diray-Arce, Holden T. Maecker, Matthew C. Altman, Ruth R. Montgomery, Patrice M. Becker, Nadine Rouphael. Nature Communications

Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma. Adolfo Aleman, Morgan van Kesteren, Ariel Kogan Zajdman, Komal Srivastava, Christian Cognigni, Jacob Mischka, Lucia Y. Chen, Bhaskar Upadhyaya, Kseniya Serebryakova, Jessica R. Nardulli, Neko Lyttle, Katerina Kappes, Hayley Jackson, Charles R. Gleason, Annika Oostenink, Gianna Y. Cai, Oliver Van Oekelen, Hala Alshammary, Dalles Andre, Radhika Banu, Katherine Beach, María Carolina Bermúdez-González, Ajai Chari, Yuexing Chen, Hearn Cho, Adolfo Firpo, Ana Silvia Gonzalez-Reiche, Eun Hye Kim, Giulio Kleiner, Florian Krammer, Jacob Mauldin, Rao Mendu, Brian Monahan, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adrianna Rossi, Ashley Salimbangon, Laryssa Sanchez, Daniel Verina, Harm van Bakel, Emilia Mia Sordillo, Carlos Cordon-Cardo, Miriam Merad, Sundar Jagannath, Ania Wajnberg, Viviana Simon, Samir Parekh. eBioMedicine

Corrigendum to “Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study” [eBioMedicine 83 (2022) 104208] (eBioMedicine (2022) 83, (S2352396422003905), (10.1016/j.ebiom.2022.104208)). Al Ozonoff, Joanna Schaenman, Naresh Doni Jayavelu, Carly E. Milliren, Carolyn S. Calfee, Charles B. Cairns, Monica Kraft, Lindsey R. Baden, Albert C. Shaw, Florian Krammer, Harm van Bakel, Denise A. Esserman, Shanshan Liu, Ana Fernandez Sesma, Viviana Simon, David A. Hafler, Ruth R. Montgomery, Steven H. Kleinstein, Ofer Levy, Chris Bime, Elias K. Haddad, David J. Erle, Bali Pulendran, Kari C. Nadeau, Mark M. Davis, Catherine L. Hough, William B. Messer, Nelson I. Agudelo Higuita, Jordan P. Metcalf, Mark A. Atkinson, Scott C. Brakenridge, David Corry, Farrah Kheradmand, Lauren I.R. Ehrlich, Esther Melamed, Grace A. McComsey, Rafick Sekaly, Joann Diray-Arce, Bjoern Peters, Alison D. Augustine, Elaine F. Reed, Matthew C. Altman, Patrice M. Becker, Nadine Rouphael. eBioMedicine

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Simon has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.